Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
Editor´s Picks
Shine News: MAH Program A Shot in the Arm for Chinese Pharmaceutical Industry(3/19/2019 )  (Premium)
  As Shanghai battles on all fronts to become a global innovation center, Zhangjiang, the sci-tech arm of the Free Trade Zone (FTZ), is leveraging the MAH program, allowing startup companies to file for new drug launches without their own manufacturing facilities.
Industry News
CanSinoBio to Launch $161M Hong Kong IPO(3/19/2019 )  (Premium)
  The management of vaccine developer CanSino Biologics has hit the road to begin marketing its up to HK$1.26 bln ($160.5 mln) IPO. The shares are scheduled to begin trading on the main board of the HKEX on March 28.
MilliporeSigma to Collaborate with GenScript to Accelerate Cell and Gene Therapy Industrialization in China(3/19/2019 )  (Premium)
  The parties envision an alliance that will accelerate the industrialization and commercialization of cell and gene therapy in China. GenScript aims to create a global-standard platform of plasmid and virus manufacturing service in the country.
ImmunoBiology and CNBG Enter Licensing Pact to Co-Develop Vaccine for Pneumococcal Disease in Greater China(3/19/2019 )  (Premium)
  ImmunoBiology, a vaccine R&D company based at Babraham Research Campus near Cambridge UK, has recently signed a licensing agreement with LIBP (Lanzhou Institute of Biological Product) a subsidiary company under China National Biotec Group (CNBG).
Korean Pharma Il-yang and Hanmi Report Robust Sales Growth in China(3/19/2019 )  (Premium)
  Two Korean pharmaceutical firms, Il-yang Pharmaceutical and Hanmi Pharmaceutical, are enjoying rapid sales growth in China after establishing local units there more than two decades ago. Il-yang¡¯s Chinese offshoot has shown the fastest revenue expansion among Korean pharmaceutical units in China.
Takeda to Invest CNY 110M into Expanding Its Chinese Manufacturing Facility(3/19/2019 )  (Premium)
  Japanese pharmaceutical company Takeda will invest CNY 110 million to expand its plant in Tianjin. The expansion involves building new warehouses, supplementary workshops and public facilities, bringing in advanced equipment, and replanning layouts of laboratories.
Merck KGaA Aims to Double China Sales by 2025(3/19/2019 )  (Premium)
  Merck KGaA has set an ambitious target of doubling its sales in China by 2025. This year, Merck will open two innovation centers in China, one in Guangzhou and the other in Shanghai, to further embed itself into the country's innovation ecosystem and enhance strategic alliances with local partners, the company said.
© Wicon International Group¡¡Support by: www.heightow.com Home | Site map | Contact Us | Links